Lewei Zhu
Overview
Explore the profile of Lewei Zhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou Y, Chen X, Li T, Gao P, Huang S, Wang X, et al.
Nutrients
. 2025 Jan;
17(2).
PMID: 39861388
: We aimed to identify neonatal circulating metabolic alterations associated with maternal gestational diabetes mellitus (GDM) and to explore whether these altered metabolites could mediate the association of GDM with...
2.
Lin Z, Li T, Huang F, Wu M, Zhu L, Zhou Y, et al.
MedComm (2020)
. 2025 Jan;
6(1):e70044.
PMID: 39802638
The optimal strategy for improving cardiometabolic factors (CMFs) in young obese individuals through diet and exercise remains unclear, as do the potential mechanisms. We conducted an 8-week randomized controlled trial...
3.
Lu X, Zhang C, Zhu L, Wang S, Zeng L, Zhong W, et al.
Adv Sci (Weinh)
. 2024 Nov;
11(47):e2400160.
PMID: 39499734
Breast cancer (BC) is a common malignancy that affects women worldwide. Although transducing beta-like 2 (TBL2), a member of the WD40 repeat protein family, has been implicated in various intracellular...
4.
Feng D, Yan Z, Fu B, Bai S, Zhu L, Gale R, et al.
Hematology
. 2024 Sep;
29(1):2402102.
PMID: 39268981
Objective: The prognosis of extra-nodal NK/T cell lymphoma (ENKTL) is poor, and the optimal therapy remains controversial. This study aims to evaluate the safety and efficacy of a new combined...
5.
Tian W, Zhu L, Luo Y, Tang Y, Tan Q, Zou Y, et al.
Adv Sci (Weinh)
. 2024 Jul;
11(36):e2309903.
PMID: 39073262
Aggressive triple-negative breast cancer (TNBC) still lacks approved targeted therapies, requiring more exploration of its underlying mechanisms. Previous studies have suggested a potential role of SAT1 (Spermidine/Spermine N1-acetyltransferase 1) in...
6.
Huang F, Zhou Y, Li T, Lin Z, Lu Y, Zhu L, et al.
Nutr Metab Cardiovasc Dis
. 2024 Jul;
34(11):2579-2588.
PMID: 39069467
Background And Aims: The relationship between vitamin D and cardiovascular health (CVH) in children remains unclear. We aimed to explore the association between vitamin D and CVH metrics using the...
7.
Xu A, Zhu L, Yao C, Zhou W, Guan Z
Cancer Drug Resist
. 2024 Jun;
7:13.
PMID: 38835343
Triple-negative breast cancer (TNBC) is among the most aggressive subtypes of the disease that does not express estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Circular RNAs...
8.
Shao R, Liu S, Liu W, Song C, Liu L, Zhu L, et al.
MedComm (2020)
. 2024 May;
5(5):e562.
PMID: 38737470
The proteasome inhibitor bortezomib (BTZ) is the first-line therapy for multiple myeloma (MM). BTZ resistance largely limits its clinical application in MM. Interleukin-33 (IL-33) exerts antitumor effects through various mechanisms,...
9.
Ye G, Chen P, Liu X, He T, Pivot X, Pan R, et al.
Gland Surg
. 2024 Apr;
13(3):374-382.
PMID: 38601287
Background: The effectiveness and safety of pyrotinib have been substantiated in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (BC). However, the role of pyrotinib as a single...
10.
Deng X, Liao T, Xie J, Kang D, He Y, Sun Y, et al.
Sci China Life Sci
. 2024 Jan;
67(4):653-662.
PMID: 38198029
PIWI-interacting RNAs (piRNAs) are a class of small noncoding RNA molecules that specifically bind to piwi protein family members to exert regulatory functions in germ cells. Recent studies have found...